AI Powers Parkinson's Cell Therapy Deal by Cellular Intelligence

Cellular Intelligence, operating under the legal entity Somite Therapeutics, has secured global rights to a promising clinical-stage cell therapy program for Parkinson's disease, previously developed by pharmaceutical giant Novo Nordisk. This strategic acquisition signals a significant push by Cellular Intelligence to leverage its advanced artificial intelligence platform to expedite the development and manufacturing of this novel therapeutic. The deal also includes an equity investment from Novo Nordisk, underscoring their continued belief in the program's potential, with the Danish company also positioned to receive future milestone payments and royalties.

The acquired program centers on an allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy. This therapy has already achieved significant regulatory milestones, including FDA Fast Track Designation and Investigational New Drug (IND) clearance, paving the way for further clinical investigation. It is currently undergoing a first-in-human Phase 1/2 clinical trial, a critical step in validating its safety and initial efficacy in Parkinson's patients. The market for Parkinson's treatments is substantial, with estimates suggesting it could reach tens of billions of dollars globally in the coming years, driven by an aging population and increasing disease prevalence.

Cellular Intelligence intends to deploy its proprietary AI-native platform to revolutionize the cell therapy lifecycle. This platform integrates advanced multiplexing technologies with a foundational model trained on an extensive dataset encompassing millions of unique perturbation conditions. The company asserts that this AI-driven approach will dramatically shorten traditional cell therapy process development and manufacturing timelines, thereby reducing costs and enhancing the scalability required for global commercial production. This focus on AI in biomanufacturing is a growing trend, aiming to overcome the inherent complexities and high costs associated with producing cell and gene therapies.

To spearhead the clinical advancement of this Parkinson's program, Cellular Intelligence has appointed Dr. Nuno Mendonça as its new Chief Medical Officer. Dr. Mendonça brings a wealth of experience as a board-certified neurologist with extensive clinical development expertise gained at prominent companies such as Bial, AbbVie, and Novartis Gene Therapies. His background spans both early and late-stage neuroscience and rare disease programs across North America and Europe, making him a key asset in navigating the complexities of clinical trials for neurodegenerative conditions.

The data generated from the ongoing clinical trials and manufacturing processes of this Parkinson's program will serve to further refine and train Cellular Intelligence's foundational AI model. The company anticipates that the insights gained will have broader applications, extending beyond this specific therapy to encompass other cell therapies and the wider field of regenerative medicine. This iterative learning process is central to the company's strategy, aiming to build a robust AI engine capable of accelerating innovation across multiple therapeutic areas.

Cellular Intelligence, also known as Somite Therapeutics, has a strong financial backing, having raised over $60 million to date. Key investors include prominent venture capital firms such as Khosla Ventures, CZI, SciFi VC, and AMD Ventures. The company's founding team comprises distinguished individuals, including AI entrepreneur Dr. Micha Breakstone, Head of the Fundamental AI Group at MIT, and four esteemed professors from Harvard Medical School and the University of Washington, highlighting a deep bench of expertise in both AI and biomedical science.